Hohl Benjamin (CIK 0001882764)

Latest company ownership

Shares held
3,250
Last filed at
Oct 1, 2025
Confidence Score
37.5
2025Q4
Confidence Score History
2023Q4 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Sep 29, 2025 Oct 1, 2025 Enliven Therapeutics, Inc. CFO Sell 25.0 -3,250 -12.38% $66.3K
Aug 27, 2025 Aug 29, 2025 Enliven Therapeutics, Inc. CFO Sell 25.0 -3,250 -12.38% $67K
Jul 28, 2025 Jul 30, 2025 Enliven Therapeutics, Inc. CFO Sell 25.0 -3,250 -12.38% $66.5K
Jul 10, 2025 Jul 14, 2025 Enliven Therapeutics, Inc. CFO Sell 41.3 -1,000 -4.17% $22.7K
Jun 27, 2025 Jul 1, 2025 Enliven Therapeutics, Inc. CFO Sell 25.0 -3,250 -12.38% $68K
Jun 13, 2025 Jun 17, 2025 Enliven Therapeutics, Inc. CFO Sell 25.0 -3,000 -11.54% $67.7K
May 27, 2025 May 29, 2025 Enliven Therapeutics, Inc. CFO Sell 25.0 -3,250 -12.38% $52.6K
Apr 28, 2025 Apr 30, 2025 Enliven Therapeutics, Inc. CFO Sell 25.0 -3,250 -12.38% $60.7K
Mar 27, 2025 Mar 31, 2025 Enliven Therapeutics, Inc. CFO Sell 25.0 -3,250 -12.38% $69.3K
Mar 24, 2025 Mar 26, 2025 Enliven Therapeutics, Inc. CFO Sell 41.3 -1,000 -4.17% $22.5K
Feb 27, 2025 Mar 3, 2025 Enliven Therapeutics, Inc. CFO Sell 20.0 -3,250 -20.00% $66.3K
Feb 5, 2025 Feb 7, 2025 Enliven Therapeutics, Inc. CFO Sell 36.3 -1,000 -7.14% $22.5K
Jan 27, 2025 Jan 29, 2025 Enliven Therapeutics, Inc. CFO Sell 20.0 -3,250 -20.00% $70.2K
Dec 13, 2024 Jan 7, 2025 Enliven Therapeutics, Inc. CFO Sell 36.3 -1,000 -7.14% $25K
Dec 27, 2024 Dec 31, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -4,250 -100.00% $94.5K
Nov 27, 2024 Dec 2, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -5,250 -100.00% $130.7K
Oct 28, 2024 Oct 30, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -6,250 -100.00% $178.5K
Oct 18, 2024 Oct 22, 2024 Enliven Therapeutics, Inc. CFO Sell 13.8 -814 -100.00% $24.4K
Oct 4, 2024 Oct 8, 2024 Enliven Therapeutics, Inc. CFO Sell 7.5 -11,488 -100.00% $316K
Oct 1, 2024 Oct 3, 2024 Enliven Therapeutics, Inc. CFO Sell 13.8 -521 -100.00% $14.3K
Sep 27, 2024 Oct 1, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -6,250 -100.00% $153.8K
Aug 27, 2024 Aug 29, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -4,250 -100.00% $95.8K
Jul 31, 2024 Aug 2, 2024 Enliven Therapeutics, Inc. CFO Sell 13.8 -991 -100.00% $27.3K
Jul 29, 2024 Jul 31, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -5,250 -100.00% $140.1K
Jul 12, 2024 Jul 16, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -3,000 -100.00% $75.2K
Jun 27, 2024 Jul 1, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -4,250 -100.00% $95.9K
May 28, 2024 May 30, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -4,250 -100.00% $98.5K
May 3, 2024 May 7, 2024 Enliven Therapeutics, Inc. CFO Sell 13.8 -1,000 -100.00% $22.5K
Apr 29, 2024 May 1, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -3,250 -100.00% $55.2K
Apr 11, 2024 Apr 15, 2024 Enliven Therapeutics, Inc. CFO Sell 7.5 -14,000 -100.00% $346.1K
Mar 27, 2024 Mar 29, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -3,250 -100.00% $59.3K
Feb 27, 2024 Feb 29, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -3,250 -100.00% $55.2K
Jan 29, 2024 Jan 31, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -3,250 -100.00% $51.4K
Dec 28, 2023 Jan 2, 2024 Enliven Therapeutics, Inc. CFO Sell 10.0 -11,870 -100.00% $178.3K
Dec 22, 2023 Dec 27, 2023 Enliven Therapeutics, Inc. CFO Sell 13.8 -1,130 -100.00% $17K